Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal

Author： Thadani Udho  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.13, Iss.17, 2012-12, pp. : 2555-2563

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Spotlight on Ranolazine in Chronic Stable Angina Pectoris

By Siddiqui M. Asif A.   Keam Susan J.  

American Journal of Cardiovascular Drugs, Vol. 6, Iss. 5, 2006-01 ,pp. : 357-359

Adis International

Access to resources Recommend Favorite

Lack of Anti-Ischemic Efficacy of the Potassium Channel Opener Bimakalim in Patients with Stable Angina Pectoris

By Burian Maria   Piske Michael   Petkovic Draga   Mitrovic Veselin  

Cardiovascular Drugs and Therapy, Vol. 18, Iss. 1, 2004-01 ,pp. : 37-46

Springer Publishing Company

Access to resources Recommend Favorite

Age-Dependent Therapeutic Effects of Once-Daily Molsidomine Used as an Add-On Treatment in Patients with Stable Angina pectoris

By  

Heart Drug, Vol. 4, Iss. 4, 2004-12 ,pp. : 184-189

Karger

Access to resources Recommend Favorite

Ranolazine extended release is a useful adjunct in the treatment of chronic stable angina pectoris

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 23, Iss. 1, 2007-01 ,pp. : 1-4

Adis International

Access to resources Recommend Favorite

Ranolazine: A Review of its Use in Chronic Stable Angina Pectoris

By Siddiqui M. Asif A.   Keam Susan J.  

Drugs, Vol. 66, Iss. 5, 2006-01 ,pp. : 693-710

Adis International

Access to resources Recommend Favorite